SEC Form 4 · accession 0001493152-26-032615
Tonix Pharmaceuticals Holding Corp. · TNXP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bradley Saenger
Officer — Chief Financial Officer
Period of report
Jun 30, 2026
Accepted (ET)
Jul 9, 2026 · 9:05 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001430306
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.001 par value | Jun 30, 2026 | J | 1,453 | $10.914 | A | 2,154 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares acquired through the Tonix Pharmaceuticals Holding Corp. 2025 Employee Stock Purchase Plan.